Clinical Trials Logo

Cigarette Smoking clinical trials

View clinical trials related to Cigarette Smoking.

Filter by:

NCT ID: NCT05233228 Recruiting - Cigarette Smoking Clinical Trials

Mobile Health Technology for Personalized Tobacco Cessation Support in Laos

SupportLaos
Start date: April 27, 2022
Phase: Phase 2
Study type: Interventional

In Lao People's Democratic Republic (Lao PDR), 51% of adult men and 7% of adult women smoke tobacco. The development and evaluation of sustainable tobacco cessation interventions suitable for widespread adoption in nations such as Lao PDR are pressing public health needs. To address this need, the investigators propose a project that adapts a theoretically and empirically based mobile health (mHealth) technology to help people quit smoking cigarettes in Lao PDR. This mHealth approach includes a fully automated, interactive, personalized, smartphone-delivered intervention for behavioral treatment, delivered through our Insightâ„¢ platform. This proposed project for Lao PDR includes 2 main phases. In the R21 Phase, the investigators will use formative research methods to adapt our intervention content to the sociocultural context, language, and communication styles of Laotians. In the subsequent R33 Phase, the investigators will conduct a randomized controlled trial (RCT) to evaluate the efficacy of our mHealth intervention and technology. Adult smokers of both sexes will be recruited through 2 large hospitals: Setthathirath Hospital in Vientiane and Champasak Hospital in Champasak Province. Participants (n=500) will be randomized to 1 of 2 treatment groups: Standard Care (SC; n=250) or Automated Treatment (AT; n=250). SC consists of brief advice to quit smoking delivered by research staff, self-help written materials, and a 2-week supply of NRT (transdermal patches). AT consists of all SC components plus a fully automated smartphone-based treatment program that involves interactive and personalized proactive messages, images, or videos. The primary health outcome of the trial is biochemically confirmed self-reported 7-day point prevalence abstinence 12 months post study enrollment. The project also aims to advance mHealth research capacity in Lao PDR and sustain the US-Lao PDR research network. The project has the potential to transform healthcare services for tobacco cessation treatment throughout the country and, ultimately, to reduce tobacco-induced morbidity and mortality significantly.

NCT ID: NCT05108649 Recruiting - Cigarette Smoking Clinical Trials

Impact of Nicotine Messaging on Beliefs and Behavior

Start date: March 2, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to examine the effect of nicotine messaging and nicotine content of study cigarettes on nicotine beliefs and subsequent use of tobacco and nicotine products.

NCT ID: NCT04965181 Recruiting - Cigarette Smoking Clinical Trials

Mindfulness-based Smoking Cessation Enhanced With Mobile Technology

Start date: July 1, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to: Aim I: Test the efficacy of a mindfulness-based text messaging program for smoking cessation ("iQuit Mindfully"), both as a standalone intervention and in combination with in-person counseling; and Aim II: Investigate the mechanisms through which mindfulness training impacts smoking cessation.

NCT ID: NCT04903028 Recruiting - Tobacco Use Clinical Trials

RTMS Targets Neural Circuits for Smoking Cessation

Start date: May 15, 2021
Phase: Phase 2
Study type: Interventional

Cigarette smoking is a significant public health concern. Transcranial magnetic stimulation (TMS) is a non-invasive form of brain stimulation that has already displayed remarkable potential for producing novel, non-pharmacological interventions for depression and cigarette smokers. In this study, investigators will use brain MRI to guide TMS therapy for smoking cessation.

NCT ID: NCT04700306 Recruiting - Cigarette Smoking Clinical Trials

Evaluation of the Added Value of Sophrology on the Intensity of Craving During Smoking Withdrawal

SOPHCIG
Start date: June 23, 2021
Phase: N/A
Study type: Interventional

To evaluate the added value of Sophrology on the intensity of craving during cigarette withdrawal.

NCT ID: NCT04525755 Recruiting - Smoking Cessation Clinical Trials

STARS (Smoking Treatment And Remote Sampling) Study

Start date: February 8, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a research study to find out if a smoking cessation medications, either varenicline or nicotine replacement products (patches or lozenges), are effective when given to smokers, remotely, as a one-time sample. Participants will either receive a sample of varenicline, nicotine patches and lozenges, or neither. This will be decided randomly. Participants have a 50%chance of receiving varenicline, a 25% chance of receiving nicotine products, and a 25% chance of receiving neither. If the participant is assigned to a group that receives free samples, they will be mailed to them free of charge. There is no requirement to use them, and it is completely up to the participants. There is also no requirement to quit in this study. The study lasts for six months, and will involve six total surveys. In addition, investigators ask that participants complete daily diaries (about 1 minute each) for the first 4 weeks of the study. Both varenicline and nicotine replacement products are well-established medications that help smokers quit.

NCT ID: NCT04449458 Recruiting - Cigarette Smoking Clinical Trials

The Positively Quit Trial for Smoking Cessation

Start date: June 10, 2020
Phase: N/A
Study type: Interventional

The main goal of the present study is to determine if a smoking cessation program designed for people living with certain chronic conditions and delivered via videoconferencing groups works better than a control condition--a program that is not designed to help with smoking but that does have the same number of group contact hours as the other program (this program is called the Attention Matched Control condition; AMC) for helping people with certain health conditions stop smoking. People in both groups will receive brief advice to quit and an offer of nicotine replacement therapy patches (NRT), as well as 12 videoconferencing group sessions. The team will measure smoking behavior over a one-year period and compare smoking rates for the treatment condition against AMC to see if the treatment condition is better at getting people living with certain health conditions to quit smoking.

NCT ID: NCT04429568 Recruiting - Nicotine Dependence Clinical Trials

THC Crossover Study

TRDRP
Start date: October 30, 2020
Phase: N/A
Study type: Interventional

This is a randomized, crossover study enrolling experienced dual cannabis-tobacco smokers (N=18) to describe the differences in THC and toxicant exposure, examining pharmacokinetic, subjective, and cardiovascular effects from smoking and vaping dry herb cannabis. This study will also examine the differences in toxicant exposure and cardiovascular disease risk between smoking cannabis and smoking tobacco cigarettes.

NCT ID: NCT04340947 Recruiting - Cigarette Smoking Clinical Trials

Cigarette Smoking Among Young Adults

ENHANCE
Start date: August 1, 2021
Phase: N/A
Study type: Interventional

This study will examine perceptions and smoking behavior of menthol and non-menthol very low nicotine cigarettes in young adult smokers. The aims are to examine perceptions and smoking behavior in the laboratory and in the natural environment. A separate sub-sample of men and women who identify as LGBTQ2S+ will also be recruited.

NCT ID: NCT04188197 Recruiting - Smoking Cessation Clinical Trials

Assisting Smokers to Switch to a JUUL E-Cigarette by Devaluing Combustible Cigarettes

RECON
Start date: August 26, 2019
Phase: Phase 3
Study type: Interventional

This study will evaluate a reward devaluation strategy in which smokers use the JUUL e-cigarette immediately before any combustible cigarettes (CCs) are smoked. This procedure is predicted to accomplish three goals: 1) the rewarding effects of CC will be disrupted because subjects will already have attained fairly high peak nicotine concentrations immediately before smoking the cigarette. This reduces the rewarding effect of smoking, in part from receptor desensitization that occurs following nicotine exposure, which reduces the response to a subsequent dose of nicotine, and in part from satiating the drive to smoke; 2) the use of the JUUL will become associated with the same cues that elicit smoking, thereby promoting the substitution of JUUL use for CC use; and 3) ad libitum nicotine intake from the JUUL and its rewarding effects will be maximized because, unlike CC, they will be experienced after a period of nicotine deprivation. Thus, despite a lower per-puff nicotine dose relative to CC, the pharmacologic impact and reinforcing effect will be maximized. The study will evaluate two flavors (Mint and Virginia Tobacco), randomly assigned, to determine if flavor assignment (similar to the subjects' usual brand of CC or different than the subjects usual brand CC) has an effect on the success of this reconditioning procedure.